Signal Genetics Increases IPO Target to up to $12.1M | GenomeWeb

NEW YORK (GenomeWeb) – Signal Genetics raised the target amount from its proposed initial public offering to up to $12.1 million.

In an amended Form S-1 filed with the US Securities and Exchange Commission on Friday, the company said it plans to offer 1.15 million shares of its common stock in its IPO at a range of $10 to $12 per share. At the midrange price of $11 the offering would bring in net proceeds of $10.3 million. If the underwriters exercise their overallotment option in full, that figure would rise to $12.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.